Radioligand Therapeutic Agent international drug patents, pharmaceutical manufacturers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 30, 2026

Radioligand therapeutic agents (RLTs) sit at the intersection of oncology targeting, radiochemistry, and biologic-adjacent regulation. Patent estates tend to be layered: (1) radionuclide-chelator and linker chemistry, (2) the targeting ligand and conjugate, (3) formulation and handling for the radiopharmaceutical (cold kit vs ready-to-use, sterilization, stability), (4) manufacturing methods, and (5) method-of-use claims tied to tumor targets, dose regimens, and patient selection. Market dynamics are shaped by (a) limited authorized manufacturing capacity, (b) CMS and payer coverage for imaging-therapy pairs, (c) site licensing and supply chain constraints for isotope production, and (d) competition from both next-generation RLTs and “combination” strategies that include imaging companion diagnostics.

The patent landscape for RLTs is rarely captured by a single “active ingredient” patent. It is closer to a network: multiple compositions-of-matter and process patents across jurisdictions, plus device and kit IP. As a result, generic entry is typically not a simple Paragraph IV pathway. Even where FDA pathway structure resembles other small-molecule drugs, the practical substitutes are constrained by radioactive supply, validated manufacturing, and tight clinical and label-defined dosing parameters. Biosimilar concepts can apply by analogy when the targeting agent is an antibody-like biologic, but radioligand RLTs are often treated as small-molecule/biologic hybrids that trigger bespoke regulatory and patent strategies.

What patents protect radioligand therapeutic agents, linkers, and radionuclide conjugates?

Most RLT patent estates cluster into predictable buckets. In practice, investors and litigators look for “claim anchors” that survive reformulation and process changes.

Which patent categories appear most in RLT estates?

1) Targeting ligand and chelator chemistry

Binding moiety (peptide, small molecule, antibody fragment, nanobody, or PSMA-targeting scaffold).
Chelators (DOTA, NOTA, HYNIC-like motifs, DTPA, and derivatives) that bind radionuclides with required kinetic and thermodynamic stability.
Linker chemistry controlling internalization, catabolism stability, and off-target release.

2) Conjugates and compositions of matter

Conjugate as a distinct molecular entity (radiolabeled precursor plus chelator architecture).
Non-radioactive precursors and kits that enable radiolabeling under GMP.
“Radiolabeled composition” claims that cover a defined specific activity range, radionuclide purity, and formulation matrix.

3) Radiolabeling processes and manufacturing methods

Conditions to attach radionuclide to the chelator (temperature, pH, reaction time).
Purification methods (HPLC, solid phase extraction, cartridge systems) to achieve radionuclidic/radiochemical purity.
Sterile filtration or aseptic processing steps for final product.
Stability and shelf-life claims for stored radiopharmaceuticals or kit components.

4) Formulation, packaging, and handling

Buffer systems, excipients, antioxidants, and surfactants.
Kit vial geometry and packaging constraints to meet radiation safety and sterility.
Release testing methods tied to radiochemical purity thresholds.

5) Method-of-use and patient selection

Indications by disease state, line of therapy, performance status.
Dose and schedule (mg-equivalent and MBq/mCi per cycle).
Imaging/selection criteria (e.g., uptake threshold, receptor expression proxies).
Combination regimens with radiosensitizers, chemotherapy, immunotherapy, or external beam radiation.

What claim types block “generic” substitutes in radioligand therapy?

RLT blocking patents are commonly:

Specific linker/chelator conjugate structures (composition-of-matter).
Radiolabeled product claims defined by purity and specific activity windows.
Process claims on radiolabeling and purification that are not easily designed around.
Method-of-use claims that align tightly with FDA labeling and standard-of-care dosing.

How do jurisdictional layers shape freedom to operate?

RLT developers typically file in:

US for Orange Book-linked exclusivities and method-of-use enforcement.
EP/UK for composition and process coverage across major oncology markets.
JP and CA for commercial scale and patent term adjustments.
AU/BR depending on local reimbursement and launch strategy.
National-phase validations for key priority chains.

When does radioligand therapeutic agent exclusivity end under US law?

RLT exclusivity timelines are determined by both patent expiry and regulatory exclusivity mechanisms. In the US, the main playbook is: “patent term + FDA exclusivities + Orange Book listings + follow-on patent durability.”

How do patent expiration dates interact with FDA exclusivity?

FDA exclusivity

New Chemical Entity (NCE): typically 5 years.
New Clinical Investigation (NCI): typically 3 years.
Orphan Drug Exclusivity: 7 years (if applicable to the approved indication).
Biologic exclusivities (12 years reference product + 6 months data exclusivity or pediatric extensions) apply when the product is regulated and labeled as a biologic pathway.

US patent term

Utility patents expire 20 years from earliest non-provisional effective filing date, subject to PTA and PTE.

Regulatory exclusivity

For many RLTs, even after data exclusivity ends, patent claims often control label use and generic entry.

What drives the “effective” exclusivity cliff for RLTs?

The practical exclusivity end is usually later than the earliest legal expiry because of:

Layered follow-on patents (formulation/process/method-of-use).
Continuations and divisionals extending claim scope.
Patent term extensions tied to approval timelines.
Settlements after Paragraph IV-type filings where the exclusivity cliff is contractually extended.

What does an RLT “patent cliff” look like?

In most RLT estates:

Early patents cover the core conjugate chemistry and chelator/linker.
Mid-term patents cover kit components, radiolabeling processes, and improved stability.
Late patents cover method-of-use dosing, patient selection, and manufacturing scale-up.

The cliff is often the later of:

last composition-of-matter expiry,
last method-of-use patent expiry tied to labeled dosing regimen,
last kit/formulation or manufacturing blocking patent,
settlement-mediated entry dates.

What is the Orange Book status of radioligand therapeutic agents, and how does it affect generic entry?

Orange Book status is a gate for ANDA-style generic entry for “small molecule” drugs. Many RLTs are not straightforward ANDA targets, but where Orange Book listings exist, they become a structured source for patent mapping.

Do radioligand therapeutics appear in the FDA Orange Book?

RLT products can show Orange Book entries when the FDA assigns them as eligible under the Orange Book framework (typically for non-biologic drug approvals). For antibody-like targeting agents, the product may track as biologic and appear in different FDA databases, shifting generic entry from ANDA mechanics to other approval constructs.

How to interpret Orange Book listings in RLT cases

Patent numbers listed under the approved NDA identify enforceable US coverage for the labeled product.
“Bolar” and “safe harbor” provisions allow certain testing, but commercialization triggers infringement risk.
If patents list multiple dosage forms or manufacturing/kit formats, generic designers must replicate purity and formulation characteristics within claim boundaries.

Why Orange Book alone underestimates RLT patent coverage

A radioligand therapeutic can have parallel non-Orange Book patents still enforceable via litigation (method-of-use, manufacturing, and kit components).
Proprietary manufacturing processes and quality specifications may be protected outside the Orange Book.
Settlements often reference nonlisted patents or broader claim sets.

Which companies have the largest radioligand therapeutic patent estates?

RLT competition is dominated by a handful of platforms built around targeting classes (PSMA, somatostatin receptor, integrin or folate pathway targets) and radionuclide chemistry. The patent estate size correlates with platform maturity and manufacturing infrastructure.

Top platform holders (by patent estate layering behavior)

PSMA radioligand therapeutics: platform owners typically extend estates across chelator/linker, dosing regimens, and kit/purification processes.
Somatostatin receptor radioligands: estates commonly emphasize conjugate stability, dosimetry-driven dosing, and patient selection.
Next-generation competitors: build around “improved” conjugates, altered chelators, higher specific activity, reduced off-target release, or different receptor-binding epitopes.

Commercial dynamics that reward larger estates

Reimbursement and clinical uptake hinge on consistent supply, validated manufacturing, and labelling aligned to payer criteria.
Larger estates correlate with longer runway for “line extension” indications (earlier line of therapy, combination regimens) and improved formulations for better stability and lower downtime in clinical sites.

How strong is the patent estate for leading radioligand therapeutics?

RLT patent strength is measured less by count and more by claim durability across:

conjugate structure,
radiolabeled product purity windows,
manufacturing method requirements,
method-of-use dosing and patient selection.

Featured snippet: what tends to make an RLT patent estate strong?

Composition-of-matter claims that cover the core conjugate structure and chelator/linker.
Manufacturing/process patents that cover radiolabeling and purification achieving radiochemical purity and specific activity.
Method-of-use patents aligned to the label and standard dosing.

Weakness patterns

Overly narrow claim coverage that requires exact structural matches.
Patent sets focused only on formulation without blocking the underlying radiolabeled conjugate.
Process patents that can be designed around with alternative purification cartridges or different radiolabeling conditions without affecting purity metrics.

What patent litigation affects radioligand therapeutic agents, and when does it matter for market entry?

RLT litigation typically centers on:

infringement of conjugate/process claims by competitor radiolabeling protocols,
invalidity arguments (obviousness, lack of written description, inadequate enablement),
scope disputes around “design-around” variants.

Why RLT disputes often turn on manufacturing

Because RLTs are sensitive to radiochemical purity, specific activity, and stability, the litigation record often includes:

batch release testing,
process parameters,
purification validation,
analytical methods to show equivalent product characteristics.

Timeline impact

Even when a patent is not scheduled to expire for years, early litigation can:

delay clinical use or compounding,
trigger settlement “hard entry dates,”
force licensing for commercialization.

Do radioligand generics face Paragraph IV challenges, and what are the likely entry risks?

Paragraph IV challenges are structurally designed for ANDA drugs. For RLTs, the entry pathway may be constrained by:

radiopharmaceutical manufacturing licensing,
isotope production/supply chain,
validated quality systems,
regulatory characterization of the product as eligible for generic substitution.

What “generic entry” means in RLTs

Same active targeting moiety with same chelator/linker and same radionuclide.
Same dosing regimen and label alignment.
Same product release criteria and radiochemical purity.

Key entry risks for would-be generic competitors

Infringement risk from composition-of-matter and process patents.
Supply chain risk from radionuclide availability (shared constraints among competing products).
Regulatory risk if the product must demonstrate comparability in radiolabeling yield, stability, and in vivo distribution.

How do radioligand therapeutic patent estates compare: PSMA vs somatostatin receptor agents?

Patent estate architecture tends to align with targeting biology and platform chemistry.

PSMA radioligand estates

Often emphasize:

chelator/linker chemistry optimized for internalization and reduced off-target salivary/kidney uptake,
specific activity and purity release requirements,
method-of-use dosing regimens tied to PSMA-targeted patient selection.

Somatostatin receptor (SSTR) radioligand estates

Often emphasize:

stability against transchelation,
patient selection by receptor expression and uptake,
dosimetry and regimen timing for peptide receptor targeting.

Comparison takeaway

Both estates are layered and manufacturing-dependent. The biggest differential is the frequency with which method-of-use claims are tied to selection and dosimetry frameworks that define label applicability.

What formulations are protected by radioligand therapeutic patents (kits vs ready-to-use)?

RLT formulations are commonly protected because formulation changes affect stability and radiolabeling yield.

Protected formulation patterns

Dry or lyophilized kits that stabilize chelator precursor and buffer matrix.
Liquid kits with controlled ionic strength and pH windows.
Antioxidant and chelation-strength additives that limit oxidative degradation.
Sterility and endotoxin control methods for final product containers.

How kits affect design-around

Even if the core conjugate is similar, competitors may be blocked by:

kit composition claims,
radiolabeling instructions encoded into the patent,
stability and release specification claims.

What manufacturing methods are protected, and how do they limit supply for competitors?

Manufacturing patents can be the single highest-friction layer for RLT entrants.

Manufacturing steps that attract IP

Radiolabeling reaction vessel configuration and control strategy.
Purification method and cartridges/resins selection.
Sterile transfer and aseptic processing steps.
Quality control assays and acceptance thresholds.

Supply chain constraints multiply IP risk

Even a licensed product still requires:

isotope allocation,
GMP facility readiness,
trained personnel and validated analytical release methods.

This creates a market where patents and operational bottlenecks reinforce each other.

What generic launch scenarios exist for radioligand therapeutic agents?

Generic entry is possible in concept but limited in practice. The realistic scenarios include:

License-based entry
- Competitor obtains rights to core conjugate/process claims, then commercializes with its own isotopes and GMP sites.
Delayed entry post-expiry
- Generic launches occur after last blocking patent expiry plus settlement or exclusivity structures.
Narrow design-around
- Competitor changes chelator/linker or purification to avoid composition/process infringement while still meeting clinical equivalence standards.
Indication-limited entry
- Entry occurs in a different indication or dosing regimen to avoid method-of-use coverage still active.

Most likely market outcome

Where RLT estates remain dense through mid/late life cycle, generic entry tends to be delayed, licensed, or limited to label carve-outs.

What is the biosimilar risk for radioligand therapeutic agents?

Biosimilar risk depends on whether the targeting moiety is regulated and treated as a biologic-like component. Many RLTs use antibody fragments or similar constructs that can trigger biosimilar-like comparability concerns.

Biosimilar-like concerns in RLTs

Structural and functional similarity of targeting moiety.
Batch-to-batch consistency of conjugate characterization.
Clinical comparability for dose, biodistribution, and safety.

Practical risk drivers

Even if a biosimilar path is technically available, radiolabeling and radiochemical properties still create a manufacturing and patent friction layer that can slow entry.

How do radioligand therapeutic patent strategies affect licensing deals and settlements?

Licensing is common because RLTs demand supply and regulatory readiness that can’t be achieved during extended litigation.

Settlement mechanics that matter

Entry date commitments.
Field-of-use restrictions (indication, line of therapy, dosing).
Royalty structures tied to net sales.
Cross-licenses covering process improvements and future formulations.

Commercial lever

A settlement can preserve a company’s ability to sell while another party waits out later method-of-use patents or manufacturing kit patents.

Key Takeaways

Radioligand therapeutic agent patent estates are layered across conjugate chemistry, radiolabeling processes, kits/formulations, manufacturing, and method-of-use dosing and patient selection.
Effective exclusivity often extends beyond earliest composition-of-matter expiry due to follow-on formulation/process/method-of-use patents and settlement-driven entry dates.
Orange Book status, where present, provides a structured patent map for US label use, but RLT freedom-to-operate is often determined by non-Orange Book patents and manufacturing method claims.
Generic entry is less about “equivalence” and more about avoiding infringement while meeting radiochemical purity, specific activity, and stability requirements under validated GMP.
Litigation and settlements can have outsized impact on market entry timing because RLT manufacturing is central to infringement analyses and because commercialization requires supply readiness.

FAQs

1) What patents typically cover radioligand therapeutic kits rather than the final radiolabeled product?
Kit composition, radiolabeling instructions, stability windows, and release testing are commonly protected, which can block “generic-like” manufacturing even when the final radiolabeled conjugate is similar.

2) How do method-of-use patents restrict radioligand therapeutic adoption even after composition-of-matter patents expire?
If method-of-use claims remain active for a labeled dosing regimen or patient selection criteria, competitors can face infringement risk when prescribing under the protected regimen.

3) What manufacturing evidence is most persuasive in radioligand patent litigation?
Radiolabeling parameters, purification workflows, radiochemical purity/specific activity release data, and analytical characterization tied to claim definitions.

4) Do radioligand therapeutic agents face longer practical exclusivity due to isotope supply constraints?
Yes. Even after legal barriers ease, radionuclide production capacity and allocation schedules can delay competitor commercialization.

5) What label or indication strategies do next-generation radioligand entrants use to reduce patent exposure?
They may target earlier lines with different dosing, use different selection criteria, or pursue combination regimens that do not read on active method-of-use claims.

References (APA)

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. Radiopharmaceuticals: current good manufacturing practice and regulatory information. https://www.fda.gov/
FDA. Exclusivity and patent information resources (Drug Products). https://www.fda.gov/